We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Merck Jumps Ship on Keytruda-Yervoy Lung Cancer Combo
Merck Jumps Ship on Keytruda-Yervoy Lung Cancer Combo
Merck announced yesterday that it is discontinuing its phase 3 nonsmall-cell lung cancer trial of Keytruda (pembrolizumab) in combination with Bristol Myers Squibb’s (BMS) Yervoy (ipilimumab), citing an unfavorable benefit-risk profile.